ISR Articles

81. COVID-19's Impact On Outsourced Manufacturing

    More than half of the biologic drug product outsourcers surveyed by ISR experienced outsourced manufacturing complications because of the pandemic. To understand how COVID-19 impacted the outsourced manufacturing sector, ISR answered a few questions on the topic in their annual contract development and manufacturing benchmarking studies.

82. Outsourcers' CMO Preferences

    In Q4, 2019, ISR asked 676 buyers of outsourced manufacturing services about which types of CMOs their organization prefers, large, global CMOs with broad capabilities or Small, niche CMOs with highly specialized capabilities. Respondents’ preference leans towards the big guys. 44% agree-strongly agree that their organization prefers large, global CMOs as compared to 28% who indicate their organization prefers smaller, niche CMOs with specialized capabilities.

83. Areas Of Growth For Oral-Dose Outsourcing

    The long history and market dominance of oral dosage forms have made this category of drug product a good candidate for outsourced manufacturing. And, according to respondents* who participated in Industry Standard Research’s 2019 Oral Dosage Forms survey, there are no signs of oral-dose outsourcing letting up.

84. Insights Into The Competitive Clinical Manufacturing Market

    There are perhaps too many options when it comes to choosing the right service provider for clinical manufacturing. Drug innovators weigh in on their selection metrics and preferences as well as reveal why vendors lose bids.

85. Letting Motivations Guide The Outsourcing Approach

    Outsourcing motivations are important considerations to identify the best outsourcing approach and should influence the type of relationships your organization develops with CMOs.

86. Revealing Response To A Hypothetical Question About Outsourcing Services

    If you were in charge of establishing a bioprocessing contract manufacturing business, which service provider attributes would you implement to ensure your company’s success? Here's how peers in the industry responded.

87. Is OSD Becoming More Complicated?

    Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Gain insight into data from ISR’s new report to provide answers to these questions and more.

88. Small & Emerging Outsourced Manufacturing Activities

    To better understand the outsourcing practices used by respondents’ companies, ISR asked research participants to provide an estimate for various manufacturing activities.

89. Small And Emerging Biopharma Companies Outsourcing Practices

    There is no question that the drug development services industry is complex, dynamic, and continuously evolving. While every sponsor company is different, all can benefit from keeping a pulse on current outsourcing practices and the activities being outsourced. Over the past year, ISR conducted several research activities with the aim of better understanding the needs of small and emerging biopharma companies and how they differ from the larger industry players. This article highlights the results of this survey.

90. Old Dog, New Tricks: How Pharma Is Innovating With Existing Technologies

    Innovation in clinical technologies sometimes comes in the shape of disruptive new technologies or as a series of incremental changes and improvements. Find out how new data is revealing positive changes and existing tech solutions are now being used in new ways.